Bristol Myers Squibb Presents Phase 1 BREAKFREE-2 Results for Zolacabtagene Autoleucel in Progressive Multiple Sclerosis at MSToronto 2026

Bristol Myers Squibb Reports Early Safety and Efficacy Results for Investigational CAR T-Cell Therapy Zola-Cel in Multiple Sclerosis Bristol Myers Squibb has announced interim safety and efficacy findings from the…

Read MoreBristol Myers Squibb Presents Phase 1 BREAKFREE-2 Results for Zolacabtagene Autoleucel in Progressive Multiple Sclerosis at MSToronto 2026

BeOne Medicines Reports Sustained Survival Benefits with TEVIMBRA-ZIIHERA in First-Line HER2-Positive Gastroesophageal Cancer

BeOne Medicines Reports Longer-Term Survival Benefits for TEVIMBRA-Based Regimens in HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd., a global oncology company, has announced new long-term survival results from the planned second…

Read MoreBeOne Medicines Reports Sustained Survival Benefits with TEVIMBRA-ZIIHERA in First-Line HER2-Positive Gastroesophageal Cancer